• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962

Professional Introduction to Compound with CAS No. 2090180-88-2 and Product Name: 3-Isoxazolecarbonitrile, 5-(aminomethyl)

The compound identified by the CAS number 2090180-88-2 and the product name 3-Isoxazolecarbonitrile, 5-(aminomethyl) represents a significant advancement in the field of pharmaceutical chemistry. This heterocyclic compound, featuring an isoxazole core with an aminomethyl substituent, has garnered considerable attention due to its versatile structural framework and potential applications in medicinal chemistry. The isoxazole ring, characterized by a five-membered structure containing an oxygen and a nitrogen atom, is a privileged scaffold in drug discovery, known for its ability to interact with biological targets in multiple ways. The presence of the nitrile group and the aminomethyl side chain further enhances its chemical reactivity and functional diversity.

In recent years, the exploration of 3-Isoxazolecarbonitrile, 5-(aminomethyl) has been extensively studied for its pharmacological properties. The compound’s unique structural features make it an attractive candidate for developing novel therapeutic agents. Specifically, the nitrile group can participate in hydrogen bonding interactions and metal coordination, while the aminomethyl group offers opportunities for further derivatization through amide or urea bond formation. These characteristics are particularly relevant in the design of small-molecule inhibitors targeting enzymes involved in critical biological pathways.

One of the most compelling aspects of this compound is its potential application in oncology research. Isoxazole derivatives have been widely investigated for their antitumor activity, and modifications at the 5-position of the isoxazole ring can significantly influence binding affinity to protein targets. Preclinical studies have demonstrated that compounds with similar structural motifs exhibit promising effects in inhibiting kinases and other enzymes overexpressed in cancer cells. The aminomethyl substituent in 3-Isoxazolecarbonitrile, 5-(aminomethyl) provides a handle for selective labeling or conjugation with other bioactive molecules, enabling the development of targeted therapies.

Moreover, the compound’s reactivity makes it a valuable intermediate in synthetic chemistry. The nitrile group can be hydrolyzed to carboxylic acids or converted into amides, while the aminomethyl group allows for alkylation or acylation reactions. These transformations are crucial for generating libraries of derivatives with tailored pharmacological properties. Recent advances in automated synthesis platforms have facilitated high-throughput screening of isoxazole-based compounds, accelerating the discovery process. Researchers have leveraged these technologies to identify novel analogs with enhanced potency and reduced toxicity.

The biological activity of 3-Isoxazolecarbonitrile, 5-(aminomethyl) has also been explored in inflammatory and infectious disease models. Studies suggest that this compound may modulate inflammatory cytokine production by interacting with intracellular signaling pathways. Additionally, its structural similarity to known antimicrobial agents has prompted investigations into its efficacy against resistant bacterial strains. The ability to fine-tune its properties through structural modifications offers a strategic advantage in addressing unmet medical needs.

In conclusion, 3-Isoxazolecarbonitrile, 5-(aminomethyl) (CAS No. 2090180-88-2) represents a promising candidate for further development in drug discovery. Its unique structural features, combined with its reactivity and biological potential, make it a valuable asset for medicinal chemists. As research continues to uncover new applications for this compound and its derivatives, it is likely to play an increasingly important role in the development of next-generation therapeutics across multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)